Monocyte-derived dendritic cells

Human dendritic cells (DCs) are specialized and most potent antigen-presenting cells that play a critical role in the regulation of innate and acquired immune responses.

A biomedical cell product based on monocyte-derived dendritic cells (BMCP) for the treatment of cancer contains mature dendritic cells loaded with the antigen of the corresponding tumor. The main task of DCs is to activate immunity against the patient’s tumor.

The biomaterial for the production of BMCP is the patient’s peripheral blood. Individual tumor antigens (the so-called tumor lysates) and (or) synthetic standardized tumor-associated antigens are used as antigenic material.

The critical advantage of BMCP is the ability to induce an immune response to weak tumor antigens that were not previously recognized by the patient’s immune system.

The clinical effect of one course of immunotherapy is manifested by the stabilization of the tumor process (in 40-50% of cases), sometimes with partial or complete regression (5-15%). Such an effect can last on average from 3 months to a year. The maximum clinical impact of such treatment can be expected if it is continuously carried out in an adjuvant mode after removal of the primary focus (after surgery) to prevent tumor recurrence and destroy invisible micrometastases.